Alexandria Real Estate Equities (ARE) is back in focus after announcing that the Multi-Modal Assessment and Phenotyping in Depression initiative with the Foundation for the National Institutes of Health has completed its critical design phase.

At a share price of $53.77, Alexandria Real Estate Equities has seen a 90 day share price return of 32.73%, while the 1 year total shareholder return is down 26.89%. This indicates that momentum has picked up recently following a challenging period.

If Alexandria Real Estate Equities' work around precision medicine has caught your attention, this can be a good moment to broaden your watchlist and check out 41 healthcare AI stocks

Bulls argue Alexandria Real Estate Equities is finally getting credit for its precision medicine tilt. Bears point to pressure on revenues and long term shareholder returns. Which story does today’s valuation appear to support?

Most Popular Narrative: 5% Overvalued

The most followed narrative puts Alexandria Real Estate Equities' fair value at $51.00, slightly below the recent $53.77 share price, which frames the current debate around upside.

The analysts have a consensus price target of $51.0 for Alexandria Real Estate Equities based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $60.0, and the most bearish reporting a price target of just $42.0.

Want to see what sits behind that tight valuation range and modest fair value cut? The narrative leans heavily on changing revenue assumptions, shifting margin expectations, and a future earnings multiple that needs careful scrutiny.

Result: Fair Value of $51.00 (OVERVALUED)

However, the story around Alexandria Real Estate Equities can change quickly if sluggish leasing persists, or if biotech funding and government health budgets put fresh pressure on occupancy and rents.

Another View on Alexandria Real Estate Equities' Valuation

The analyst narrative calls Alexandria Real Estate Equities about 5% overvalued at $53.77 versus a $51.00 fair value. Yet the P/S ratio of 3.2x sits well below both peers and the broader Health Care REITs group at 7x, and below a 4.6x fair ratio estimate. Is the market overpricing near term risks or underpricing longer term potential?

Next Steps

With sentiment clearly mixed around Alexandria Real Estate Equities, this can be a good moment to review the numbers yourself and reach a balanced view based on the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Alexandria Real Estate Equities?

Alexandria Real Estate Equities may be front of mind today, but your next opportunity could sit in a very different corner of the market. Use the Simply Wall Street Screener to compare quality, value and risk across sectors before prices move away from you.

• Target potential value opportunities early by scanning companies that show strong fundamentals and attractive pricing through the 49 high quality undervalued stocks.
• Prioritise resilience by reviewing the 85 resilient stocks with low risk scores and focus on businesses that score well on financial strength and volatility measures.
• Stay ahead of the crowd by checking the screener containing 21 high quality undiscovered gems where smaller, less followed stocks with solid fundamentals are grouped for closer inspection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.